COPD is associated with an abnormal inflammatory response in the lungs, with extra-pulmonary manifestations. Cardiovascular disease is one of the major causes of mortality in COPD, particularly in patients with mild to moderate severity. [3, 4] The likelihood of identifying cardiovascular subclinical abnormalities in patients with COPD during daily clinical practice strongly depends on the diagnostic techniques used.
The discovery of novel biomarkers helps identify cardiovascular risk in patients with COPD. Ideally, the biomarker should be inexpensive, noninvasive, and easily assessable. [5] C-reactive protein (CRP) has been proposed as one such biomarker, but it does not provide additional prognostic information beyond traditional risk factors in the general population. [6] Microalbuminuria (MAB) is a sensitive marker of cardiovascular risk. [7] MAB is believed to reflect a state of generalized endothelial dysfunction. The presence of MAB is consistently associated with worse cardiovascular outcomes in patients with diabetes and hypertension but most importantly in the general population. [8] It has a stronger association with cardiovascular events and death than CRP. [6] A limited number of studies have evaluated the presence of MAB in patients with COPD, mostly during exacerbations. [9, 10] The aim of this study is to determine the prevalence of MAB in a group of stable COPD patients and evaluate the relationship of MAB levels with clinical and physiological descriptors of COPD severity.
Materials and Methods
This was a cross-sectional study conducted on 150 patients who were diagnosed with COPD as per GOLD guidelines in the Outpatient Department of Pulmonary Medicine during January 2015-December 2015.
Inclusion criteria
All patients who came to outpatient clinic aged diagnosed as a case of COPD, based on GOLD guidelines (history of smoking >10 pack-years and a postbronchodilator forced expiratory volume in 1 s [FEV 1 ]/forced vital capacity <0.70), [11] who are stable for 6 weeks and received optimal therapy. Exclusion criteria 1. History of renal disease or presence of macroalbuminuria (urinary albumin-to-creatinine ratio >300 mg/g) 2. Previously diagnosed diabetes mellitus 3. Cardiovascular disease 4. Comorbidities such as malignancy, fever, urinary tract infections 5. Asthma 6. Hypertension.
Procedure
The study was approved by the Ethical and Research Committee. The selected patients were briefed about the study and written informed consent was obtained.
The enrolled patients were given a questionnaire concerning age, gender, height, weight, presenting symptoms, history and duration of COPD, history of smoking.
Lung function tests were done and COPD was classified as per GOLD guidelines. [11] Arterial blood gases, body mass index (BMI), and BP were measured. The 6-min walk distance (6MWD) was measured according to the American Thoracic Society guidelines. [12] Dyspnea was evaluated by the modified Medical Research Council (mMRC) scale. [13] The FEV 1 %, BMI, 6MWD, and mMRC values were integrated into the BODE index. [14] According to the American Diabetes Association, screening for MAB was done by measuring the urinary albumin-to-creatinine ratio in a random spot urine collection. [15] MAB was defined when the urinary albumin-to-creatinine ratio was between 20 mg/g in men and 30 mg/g in women and the upper threshold of 299 mg/g for both sexes. [16] 
Statistical analysis
Statistical analysis was performed using the IBM's Statistical Package for Social Sciences (SPSS) software version 19 (IBM SPSS, Inc. Chicago, Illinois). The results are expressed as percentages or mean ± standard deviation as specified. Pearson's Chi-square method was used for comparing proportions and percentages, whereas Student's t-test was used for comparison of continuous variables. Stepwise logistic regression was performed using MAB as the dependent variable. P < 0.05 was taken as statistically significant.
Results
A total of 150 patients diagnosed with COPD were enrolled in the study. There were 145 male patients and five female patients. Their mean age was 59.67 years, mean smoking pack-years was 28.91, and mean BMI was 24.94. There were 38 (25%) GOLD It was observed that as the pack-years increased, the risk of MAB had also increased. Application of Chi-square test showed a significant association of pack-years with MAB (P < 0.0001) Table 2 .
Majority of COPD patients with MAB had FEV 1 % 30-49 (33.3%) and FEV 1 %≤30 (56.0%), when compared to FEV 1 % 50-80 and FEV 1 % ≥81 (10.53% and 12.5% respectively). Also it was observed, that as the FEV 1 % decreases, the risk of MAB had also increased (P < 0.0001) Table 3 .
MAB was significantly more in COPD patients having PaO 2 below 70 mm Hg as compared to COPD patients having PaO 2 above 70 mm Hg (100% vs. 7.14%, respectively, P < 0.0001), which indicates COPD patients with MAB were more hypoxemic Table 4 .
MAB was significantly more in COPD patients having PaCO 2 ≥45 mm Hg as compared to COPD patients having PaCO 2 <45 mm Hg (67.86% vs. 8.51%, respectively, P < 0.0001), which indicates COPD patients with MAB were more hypercapnic Table 5 .
The BODE index was compared with the prevalence of MAB. 47.62% of COPD patients with BODE index ≥3 had MAB when compared to 9.09% COPD patients with BODE index <3, and it was statistically significant P = 0.0001.
Stepwise logistic regression analysis with MAB as the dependent variable showed that smoking pack-years (odds ratio [OR]: 2.29; 95% CI: 1.54-3.41), 
Discussion
Cardiovascular disease is one of the major causes of mortality in COPD, particularly in patients with mild to moderate severity. [3, 4] MAB is a sensitive marker of cardiovascular risk. [7] Moreover, it reflects a state of generalized endothelial dysfunction. It is consistently associated with worse cardiovascular outcomes in patients with diabetes and hypertension but most importantly in the general population also. [8, 17] In the present study, a total of 46 patients (30%) out of 150 stable COPD patients had MAB. A recent publication by Casanova et al. [18] observed the prevalence of MAB to be 24% in stable COPD patients. In a study by Bulcun et al., [19] it was found that the prevalence of MAB to be 39%. In a study by Mehmood and Sofi, [20] it was found that MAB was more frequent in COPD patients compared to smokers without obstruction (20.6% vs. 7.4%, respectively).
In the present study, majority of COPD patients with MAB had GOLD stage of III (33.3%) and Stage IV (56.0%), and this association was statistically significant; P = 0.0001. In a study by Casanova et al., [18] any association between MAB and spirometric severity of COPD was not observed. Mehmood and Sofi [20] found that COPD patients with MAB had significantly lower levels of FEV 1 .
In this study, it was observed that as the smoking pack-years increased, the risk of MAB had also increased. In a study by Casanova et al., [18] the number of pack-years smoked was not associated with the levels of MAB. In another study by Mehmood and Sofi, [20] MAB was significantly associated with higher pack-years of smoking exposure possibly because of endothelial cells could be directly affected by the cigarette smoke products.
In the present study, majority of COPD patients with MAB had mMRC dyspnea Grade IV (39.13%) and Grade III (36.95%) indicating that COPD patients with MAB were more dyspneic and were statistically significant. In another study by Mehmood and Sofi, [20] majority of COPD patients with MAB had mMRC dyspnea Grade III-IV (32.5%).
MAB was significantly more in COPD patients having PaO 2 below 70 mm Hg as compared to COPD patients having PaO 2 above 70 mm Hg (100% vs. 7.14%, respectively, P < 0.0001), which indicates COPD patients with MAB were more hypoxemic. In a study [18] and Mehmood and Sofi, [20] patients with COPD and MAB were more hypoxemic than those without MAB, and it was inversely related to PaO 2 .
MAB was significantly more in COPD patients having PaCO 2 ≥45 mm Hg as compared to COPD patients having PaCO 2 <45 mm Hg (67.86% vs. 8.51%, respectively, P < 0.0001), which indicates COPD patients with MAB were more hypercapneic. In a study by Casanova et al. [18] and Mehmood and Sofi, [20] the MAB levels were positively related with the PaCO 2 level.
In 6MWD test, it was observed as exercise capacity decreases, the prevalence of MAB increases. Kumar [21] also obtained an inverse relationship of 6MWD with MAB levels in their study.
The BODE index was compared with the prevalence of MAB. 47.62% of COPD patients with BODE index ≥3 had MAB when compared to 9.09% of COPD patients with BODE index <3 and it was statistically significant.
Celli et al. [14] showed that BODE index is a better predictor of mortality for COPD patients than the classical FEV 1 values alone. Increased BODE index values are observed in patients with more severe disease. Similarly, in our study, MAB which is predictive for cardiovascular disease risk was related with BODE index and hypoxemia and also related with pulmonary function parameters such as FEV 1 %.
Stepwise logistic regression analysis with MAB as the dependent variable showed that smoking pack-years (OR: 2.29; 95% CI: 1.54-3.41), low FEV 1 % (OR: 1.04; 95% CI: 0.98-1.10), and PaO 2 (OR: 0.68; 95% CI: 0.57-0.83) were independent and significant predictors of MAB. There was a negative association of the PaO 2 and MAB in patients with COPD.
The study has some limitations: 1. The less number of women included in study made impossible any evaluation of possible sex differences in MAB, possibly due to less prevalence of female smokers in this region 2. We had no follow-up MAB levels in COPD patients to look for stability of MAB levels over a period 3. We did not compare the MAB with other biomarkers, such as CRP. However, CRP is not a biomarker that has proven useful in COPD, and therefore, is not a comparator gold standard 4. There was no control group to compare the variation in MAB in patients who are smokers without COPD.
Conclusions
The determination of MAB is simple, inexpensive, and noninvasive. Thus, MAB in patients with severe COPD, with hypoxemia or higher BODE index (≥3) should be examined in regular periods to determine whether there is a risk of cardiovascular morbidity and mortality.
Longitudinal studies in different settings with larger populations are needed to evaluate the practical role of MAB in patients with COPD.
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